Article
Immunology
Azam Safary, Kamal Esalatmanesh, Amir Taher Eftekharsadat, Mohammad -Reza Jafari Nakjavani, Alireza Khabbazi
Summary: Vaccination against COVID-19 is important for achieving herd immunity and controlling the pandemic. However, a small number of people may develop autoimmune rheumatic diseases (ARDs) as a rare adverse reaction to the vaccines. This study identifies individuals who developed de-novo ARDs after COVID-19 vaccination, with a higher prevalence among those who received the AstraZeneca vaccine. Prompt diagnosis and treatment can prevent irreversible organ damage.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Zixi Yi, Zhongqiang Yao, Dan Xu, Chuanhui Xu, Wenqiang Fang, Zhanfei Guo, Yong Wang, Jianlin Huang, Qin Li, Hong Zhang, Anbin Huang, Lijun Wu, Zhenbiao Wu, Huifang Guo, Fengxiao Zhang, Jing Lu, Zhenchun Zhang, Zhongming Yu, Zhanyun Da, Li Luo, Bin Wu, Henglian Wu, Lin Zeng, Rong Mu
Summary: The study highlights the intentions and actual vaccination rates among patients with rheumatic diseases in China. The majority of patients intended to get vaccinated, but the actual vaccination rate was low. Male, employed, high-income patients and those with inactive disease showed a more positive attitude towards vaccination. Concerns about adverse events and disease flare were the main factors affecting vaccination willingness. Furthermore, a significant portion of patients felt that they did not receive enough information about the COVID-19 vaccine from their doctors.
Article
Biotechnology & Applied Microbiology
Guillermo Guaracha-Basanez, Irazu Contreras-Yanez, Everardo alvarez-Hernandez, Carla Marina Roman-Montes, Graciela Meza-Lopez Y. Olguin, Maria Jose Morales-Graciano, Salvador Saul Valverde-Hernandez, Ingris Pelaez-Ballestas, Virginia Pascual-Ramos
Summary: Vaccine hesitancy (VH) has been identified as a threat in combating the COVID-19 pandemic, particularly among patients with rheumatic diseases in Mexico. The study aimed to quantify VH phenomenon and validate a questionnaire in this population, finding that the COVID-19 VH questionnaire showed good psychometric properties and sensitivity to change.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Medicine, General & Internal
Marta Rorat, Dorota Zarebska-Michaluk, Justyna Kowalska, Krzysztof Kujawa, Magdalena Rogalska, Dorota Kozielewicz, Beata Lorenc, Katarzyna Sikorska, Piotr Czupryna, Beata Bolewska, Jadwiga Maciukajc, Tomasz Piekos, Regina Podlasin, Anna Dworzanska, Wlodzimierz Mazur, Michal Brzdek, Anna Szymanek-Pasternak, Robert Flisiak
Summary: Patients with systemic autoimmune rheumatic disease (SARD) are more susceptible to SARS-CoV-2 infection. This study compared the characteristics, severity, course, and outcomes of COVID-19 in SARD patients with the non-SARD group. Factors associated with prognosis, including remdesivir therapy efficacy, were also examined. The study found that SARD patients had longer hospital stays, higher mortality rates, and a greater need for oxygen therapy compared to the non-SARD group. Age, the presence of cardiovascular disease, severity of condition on admission, and higher inflammatory marker values were identified as risk factors for death in the SARD group. Remdesivir treatment showed a trend towards improved mortality in SARD patients but was not statistically significant. Overall, SARD patients had worse outcomes and were more likely to have other chronic diseases.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Katja Lakota, Katja Perdan-Pirkmajer, Alojzija Hocevar, Snezna Sodin-Semrl, Ziga Rotar, Sasa Cucnik, Polona Zigon
Summary: Patients with autoimmune diseases are more susceptible to infections, and COVID-19 may trigger autoimmune responses, but autoantibodies following SARS-CoV-2 infection are likely transient. The risk of SARS-CoV-2 infection in patients with systemic autoimmune rheumatic diseases is slightly higher, but the course of the disease seems similar to the general population.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Abeer N. Alshukairi, Awad Al-Omari, Abdurahman Albeity, Thamir A. Alandijany, Ahmed M. Hassan, Sherif A. El-Kafrawy, Ashraf Dada, Mohammad K. Al Hroub, Aiman El-Saed, Lina S. Bissar, Radwan M. Daghmush, Saeed M. G. Al-Ghamdi, Stanley Perlman, Esam I. Azhar, Hussein Halabi
Summary: This study evaluated the humoral responses to COVID-19 vaccination and breakthrough infections in low risk rheumatic disease patients during the Delta Variant Era. The results showed high prevalence of SARS-CoV-2 neutralizing antibodies and self-limiting breakthrough infections in these patients. Further studies are needed to assess the impact of viral immune escape responses in rheumatic disease patients during the Era of Omicron.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2022)
Article
Rheumatology
Christian Ammitzboll, Marianne Kragh Thomsen, Jakob Bogh Andersen, Jens Magnus Berth Jensen, Marie-Louise From Hermansen, Anders Dahl Johannsen, Mads Lamm Larsen, Clara Elbaek Mistegaard, Susan Mikkelsen, Fruzsina Szabados, Signe Risbol Vils, Christian Erikstrup, Ellen-Margrethe Hauge, Anne Troldborg
Summary: This study aimed to investigate the effect of either a booster vaccine or revaccination on the antibody response to COVID-19 mRNA vaccines in rheumatic disease patients treated with rituximab. The study found that most patients had impaired humoral response after the booster dose or revaccination, and approximately one-third of the patients showed seroconversion. Measurable B cells before boosting or revaccination were the strongest predictor of antibody response.
Article
Rheumatology
Charalampos Papagoras, George E. Fragoulis, Nikoleta Zioga, Theodora Simopoulou, Kleopatra Deftereou, Eleni Kalavri, Evangelia Zampeli, Nafsika Gerolymatou, Evangelia Kataxaki, Konstantinos Melissaropoulos, Stylianos Panopoulos, Kalliopi Fragiadaki, Gerasimos Evangelatos, Vasiliki-Kalliopi Bournia, Aikaterini Arida, Anastasios Karamanakos, Maria Pappa, Alexandros Panagiotopoulos, Christos Koutsianas, Georgia Mparouta, Theodoros Dimitroulas, Stamatis-Nick Liossis, Maria G. Tektonidou, Evrydiki Kravvariti, Nikolaos Kougkas, Panagiotis Georgiou, Paraskevi Voulgari, Antonia Elezoglou, Dimitrios P. Bogdanos, Dimitrios Vassilopoulos, Petros P. Sfikakis
Summary: Vaccinated patients with systemic rheumatic diseases who experience breakthrough COVID-19 have better outcomes compared to unvaccinated patients with similar disease characteristics. This highlights the importance of COVID-19 vaccination in vulnerable populations like those with SRDs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Priyanka Gaur, Hardik Agrawat, Anuj Shukla
Summary: In patients with AIRD, older individuals are more willing to get vaccinated than younger ones, while those with lower education levels are more hesitant. Common reasons for hesitancy include indecision, fear of vaccine side effects, and disease worsening.
RHEUMATOLOGY INTERNATIONAL
(2021)
Review
Immunology
Yan Xie, Yang Liu, Yi Liu
Summary: Concerns about disease flare among patients with rheumatic diseases after COVID-19 vaccination are not supported by current evidence. Flares triggered by vaccinations are generally mild and do not require additional treatment. Therefore, it is recommended for patients with rheumatic diseases to receive the COVID-19 vaccination when their diseases are stable.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Yi Wye Lai, Choon Guan Chua, Xin Rong Lim, Prabath Joseph Francis, Chuanhui Xu, Hwee Siew Howe
Summary: This study reports on four cases of myocarditis in patients with autoimmune rheumatic diseases following COVID-19 mRNA vaccination and reviews the literature on post-vaccination myocarditis and ARD flares. In contrast to isolated myocarditis, these patients had myocarditis associated with ARD flares and required increased immunosuppression for resolution.
Article
Biotechnology & Applied Microbiology
Guillermo Arturo Guaracha-Basanez, Irazu Contreras-Yanez, Everardo Alvarez-Hernandez, Greta Reyes-Cordero, Diana Elsa Flores-Alvarado, Susana Aidee Gonzalez-Chavez, Dionicio Angel Galarza-Delgado, Perla Rocio Martinez-Leyva, Jose Francisco Moctezuma-Rios, Conrado Garcia-Garcia, Gabriel Medrano-Ramirez, Alfonso Gastelum-Strozzi, Cesar Pacheco-Tena, Ingris Pelaez-Ballestas, Virginia Pascual-Ramos
Summary: This study aimed to identify factors associated with COVID-19 vaccine acceptance in Mexican outpatients with rheumatic diseases. Education level, corticosteroid use, patient perceptions about the vaccine and the pandemic severity, patient civil/moral position regarding COVID-19 vaccine, and previous influenza vaccination were associated with vaccine acceptance.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Massimo L'Andolina, Lorenzo Dagna, Antonio Tavoni, Francesco Caso, Francesco Ursini, Piero Ruscitti, Maurizio Caminiti, Rosario Foti, Valeria Riccieri, Serena Guiducci, Roberta Pellegrini, Elisabetta Zanatta, Giuseppe Varcasia, Domenico Olivo, Pietro Gigliotti, Giovanna Cuomo, Giuseppe Murdaca, Riccardo Cecchetti, Rossella De Angelis, Nicoletta Romeo, Francesca Ingegnoli, Franco Cozzi, Veronica Codullo, Ilaria Cavazzana, Michele Colaci, Giuseppina Abignano, Maria De Santis, Ennio Lubrano, Enrico Fusaro, Alessandra Della Rossa, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Silvia Bellando-Randone, Elisa Visalli, Ylenia Dal Bosco, Giorgio Amato, Daiana Giannini, Silvia Bilia, Francesco Masini, Greta Pellegrino, Erika Pigatto, Elena Generali, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Rodolfo Caminiti, Daniela Scorpiniti, Tommaso Ferrari, Corrado Campochiaro, Veronica Brusi, Micaela Fredi, Liala Moschetti, Fabio Cacciapaglia, Laura Gragnani, Monica Monti, Serena Lorini, Sabrina Rosaria Paparo, Francesca Ragusa, Valeria Mazzi, Giusy Elia, Silvia Martina Ferrari, Ilenia Di Cola, Marta Vadacca, Sebastiano Lorusso, Simone Barsotti, Maria Letizia Aprile, Tasso Marco, Mario Miccoli, Silvia Bosello, Marco Matucci-Cerinic, Salvatore D'Angelo, Andrea Doria, Franco Franceschini, Riccardo Meliconi, Florenzo Iannone, Roberto Giacomelli, Anna Linda Zignego, Poupak Fallahi, Alessandro Antonelli
Summary: The prevalence of symptomatic Covid-19 was significantly higher in ASD patients in Italy compared to the general population, with variations in different regions and subgroups. Patients undergoing specific treatments or with specific clinical features showed lower prevalence rates. This suggests the importance of developing targeted prevention/management strategies during the current pandemic.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Immunology
Sinem Nihal Esatoglu, Koray Tascilar, Hakan Babaoglu, Cemal Bes, Berna Yurttas, Servet Akar, Ozlem Pehlivan, Cansu Akleylek, Duygu Tecer, Emire Seyahi, Tuba Yuce-Inel, Nilufer Alpay-Kanitez, Erdal Bodakci, Emre Tekgoz, Seda Colak, Ertugrul Cagri Bolek, Suleyman Serdar Koca, Umut Kalyoncu, Ozan Cemal Icacan, Serdal Ugurlu, Hande Ece Oz, Vedat Hamuryudan, Gulen Hatemi
Summary: This study found that among patients with inflammatory rheumatic diseases (IRDs) and COVID-19, factors such as glucocorticoid use, chronic kidney disease, pulmonary disease, and obesity were associated with worse outcomes, while biologic disease-modifying antirheumatic drugs did not seem to be associated with worse outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Psychology, Multidisciplinary
Maria Correa-Rodriguez, Blanca Rueda-Medina, Jose-Luis Callejas-Rubio, Raquel Rios-Fernandez, Javier de la Hera-Fernandez, Norberto Ortego-Centeno
Summary: This study aims to evaluate vaccine literacy skills in patients with autoimmune diseases and analyze the associations between vaccine literacy skills and sociodemographic characteristics. The study found that vaccine literacy levels were associated with area of residence, civil status, socioeconomic status, and educational attainment. These factors need to be considered to ensure optimal vaccine literacy levels in patients with autoimmune diseases.
CURRENT PSYCHOLOGY
(2023)
Article
Rheumatology
Tatiana Nevskaya, Leonardo M. Calderon, Murray Baron, Janet E. Pope
Summary: Digital ulcers in systemic sclerosis patients lead to increased utilization of healthcare resources, including tests, visits, and aids. Even after adjusting for disease severity in other organ systems, the presence of digital ulcers remains a significant predictor of more frequent physician visits and more tests.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Naomi J. Patel, Kristin M. D'Silva, Matthew D. Li, Tiffany Y. T. Hsu, Michael DiIorio, Xiaoqing Fu, Claire Cook, Lauren Prisco, Lily Martin, Kathleen M. M. Vanni, Alessandra Zaccardelli, Yuqing Zhang, Jayashree Kalpathy-Cramer, Jeffrey A. Sparks, Zachary S. Wallace
Summary: COVID-19 patients with rheumatic disease have more severe lung involvement. Higher pulmonary x-ray (PXS) scores are associated with mechanical ventilation and death.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Kiem Oen, Karine Toupin-April, Brian M. Feldman, Roberta A. Berard, Cia'ran M. Duffy, Lori B. Tucker, Jiahao Tian, Dax G. Rumsey, Jaime Guzman
Summary: This study validates the JIA parent global assessment as a valid measure of health-related quality of life. Comparisons with other HRQoL measures show good construct validity. However, reliability estimates and measurement errors were unsatisfactory, likely due to the time interval between assessments. Causal pathway analysis confirms previous findings.
Article
Rheumatology
Medha Barbhaiya, Jaime E. Hart, Susan Malspeis, Sara K. Tedeschi, Trang VoPham, Jeffrey A. Sparks, Elizabeth W. Karlson, Francine Laden, Karen H. Costenbader
Summary: This study aimed to investigate the association between UV radiation exposure and the risk of developing SLE. The results showed that there was no significant association between UV exposure and SLE risk, but higher UV exposure was associated with increased risk of malar rash.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Siobhan Deshauer, Mats Junek, Murray Baron, Karen A. Beattie, Margaret J. Larche
Summary: This study examined the impact of pregnancy on disease activity in women with systemic sclerosis. The results showed that having at least one pregnancy after diagnosis did not significantly affect long-term renal, respiratory, or global function outcomes. However, postpartum complications should still be monitored.
JOURNAL OF SCLERODERMA AND RELATED DISORDERS
(2023)
Letter
Rheumatology
Michael Putman, Jilaine Bolek Berquist, Eric M. Ruderman, Jeffrey A. Sparks
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Hemin Lee, Jeffrey A. Sparks, Su Been Lee, Kazuki Yoshida, Joan E. Landon, Seoyoung C. Kim
Summary: This study aims to determine the accuracy of ICD-10 diagnosis codes for rheumatoid arthritis (RA) serostatus using a US claims database (Optum Clinformatics Data Mart) and compare the results to a previous study. The results showed that the PPVs for seropositive and seronegative RA in the Optum database were lower than those in MarketScan, but improved when more restricted definitions of M05 and M06 were used.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2023)
Article
Rheumatology
Joanna E. Parkes, Jessica F. Boehler, Ning Li, Ryan M. Kendra, Terrance P. O'Hanlon, Eric P. Hoffman, Jennifer M. Peterson, Frederick W. Miller, Lisa G. Rider, Kanneboyina Nagaraju
Summary: Rituximab treatment in myositis patients is associated with differential mRNA and microRNA expression, and the beneficial effect may be mediated by increased ESR1 signaling in addition to B-cell depletion.
Article
Rheumatology
Melissa Morales, Tchilabalo D. Alayi, Shefa M. Tawalbeh, Agnes Sydenstricker, Rita Spathis, Hanna Kim, Kanneboyina Nagaraju, Yetrib Hathout, Lisa G. Rider
Summary: This study aimed to identify and validate biomarkers in children with juvenile dermatomyositis (JDM) using a multiplexing tandem mass tag urine proteome profiling approach. The results confirmed the presence of elevated cathepsin D and galectin-3 binding protein in the urine of JDM patients, supporting previous findings in myositis patients. The study also identified novel candidate biomarkers related to myositis.
Article
Rheumatology
Rodolfo Curiel, William Nguyen, Gulnara Mamyrova, Derek Jones, Alison A. Ehrlich, Kathleen Brindle, Shahriar Haji-Momenian, Robert Sheets, Hanna Y. Kim, Olcay G. Jones, Lisa Rider
Summary: This 24-week open-label study aimed to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (DM). Ten patients with moderate disease activity were enrolled to examine the safety of subcutaneous abatacept and patient responses. The results showed improvements in disease activity, decrease in glucocorticoid doses, and decrease in muscle edema.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Oncology
Cesar A. Virgen, Jeffrey A. Sparks, Anju Nohria, Meabh J. O'Hare, Amrita Goyal, Jordan T. Said, Marianne Tawa, Nicole R. LeBoeuf, Thomas S. Kupper, David C. Fisher, Cecilia Larocca
Summary: This study identified muscular immune-related adverse events associated with mogamulizumab in T-cell lymphoma patients. Among 42 patients, 5 cases of mogamulizumab-associated myositis and/or myocarditis were found, with 2 cases also affected by myasthenia gravis. The incidence of these muscular adverse events may be higher than previously reported and can occur late in the treatment.
Article
Environmental Sciences
John Volckens, Erin N. Haynes, Sharon P. Croisant, Yuxia Cui, Nicole A. Errett, Heather F. Henry, Jennifer A. Horney, Richard K. Kwok, Sheryl Magzamen, Ana G. Rappold, Lingamanaidu Ravichandran, Les Reinlib, Patrick H. Ryan, Daniel T. Shaughnessy
Summary: This commentary discusses the lack of research on the nature and effects of disasters on human health and the challenges in developing cost-effective sensors for exposure assessment. The panel of experts highlights the need for scalable, reliable, and versatile sensor technologies, as well as renewed efforts in support of disaster research facilitation, collaboration, and preparedness.
ENVIRONMENTAL HEALTH PERSPECTIVES
(2023)
Review
Rheumatology
Rathnam Venkat, Zachary S. S. Wallace, Jeffrey A. A. Sparks
Summary: This review examines the impact of disease-modifying antirheumatic drugs (DMARDs) on COVID-19 severity and vaccine immunogenicity, and discusses the COVID-19 outcomes in rheumatoid arthritis (RA) patients. The findings suggest that rituximab is associated with severe COVID-19 and impaired vaccine immunogenicity, while JAK inhibitors and glucocorticoids have a modest association with these effects. TNF inhibitors may have a protective effect against severe COVID-19 and do not seem to affect vaccine immunogenicity. Holding methotrexate doses around COVID-19 vaccination improves immunogenicity but may increase the risk of RA flare.
CURRENT RHEUMATOLOGY REPORTS
(2023)
Article
Rheumatology
R. E. Borgia, M. J. Gurka, S. L. Filipp, M. Elder, M. Cardel, N. J. Shiff, CARRA Registry Investigators
Summary: This study examines the connection between race/ethnicity and the Patient-Reported Outcomes Measurement Information System (PROMIS) in childhood-onset systemic lupus erythematosus (cSLE) patients. The study found that PROMIS global health was lower among multiethnic cSLE patients compared to the general pediatric population, but there was no significant association between race/ethnicity and PROMIS scores.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith
Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
